Drug Safety Oversight Initiatives Spur CDRH Postmarket Soul-Searching
This article was originally published in The Gray Sheet
Executive Summary
The recent spotlight on drug safety is prompting FDA's Center for Devices & Radiological Health to re-examine its regulatory approach to devices